Safety and pharmacology of AMY109, a long-acting anti–interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial
AMY001JG study; JapicCTI-183841. Trial registration date: January 25, 2018. Date of first participant's enrolment: February 26, 2018.
Authors
- Chun‐An Chen (ORCID: https://orcid.org/0000-0001-8880-7113)
- Shunji Matsuki
- Ayako Nishimoto (ORCID: https://orcid.org/0000-0002-8654-7423)
- Junnosuke Matsushima
- Peng‐Hui Wang (ORCID: https://orcid.org/0000-0002-6048-8541)
- Sheng-Mou Hsiao
- Mayuko Sekiya
- Ryuzo Hanada
- Kiyohiko Nakai
- Mari Sawada
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- Far Eastern Memorial Hospital (TW)
- Kurashiki Medical Center (JP)
- Chugai Pharma (United States) (US)
- SOUSEIKAI Global Clinical Research Center (JP)
- Mirai Hospital (JP)
Publication Details
- Journal
- F&S Reports
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1016/j.xfre.2025.04.009
- Citations
- 3
- Primary Topic
- Endometriosis Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.09